Health Care [ 9/12 ] | Life Sciences Tools & Services [ 26/75 ]
NASDAQ | Common Stock
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States.
The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.
It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process.
In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies.
The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies.
Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011.
The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 10, 24 | 0.05 Increased by +133.33% | 0.01 Increased by +400.00% |
| Sep 11, 24 | 0.11 Increased by +157.89% | -0.03 Increased by +466.67% |
| Jul 18, 24 | 0.01 Increased by +105.26% | -0.16 Increased by +106.25% |
| Mar 12, 24 | -0.16 Increased by +11.11% | -0.06 Decreased by -166.67% |
| Dec 12, 23 | -0.15 Decreased by -12.40 K% | -0.17 Increased by +11.76% |
| Sep 13, 23 | -0.19 Decreased by -850.00% | -0.10 Decreased by -90.00% |
| Jul 24, 23 | -0.19 Decreased by -533.33% | -0.12 Decreased by -58.33% |
| Mar 15, 23 | -0.18 Decreased by -460.00% | -0.04 Decreased by -350.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Oct 31, 24 | -14.06 M Decreased by -221.50% | 728.00 K Increased by +135.15% | Decreased by -5.18% Increased by +71.07% |
| Jul 31, 24 | 14.06 M Increased by +11.94% | 1.31 M Increased by +151.17% | Increased by +9.34% Increased by +145.71% |
| Apr 30, 24 | 14.00 M Increased by +7.11% | -109.00 K Increased by +95.74% | Decreased by -0.78% Increased by +96.03% |
| Jan 31, 24 | 12.02 M Decreased by -5.90% | -2.53 M Decreased by -3.73% | Decreased by -21.05% Decreased by -10.24% |
| Oct 31, 23 | 11.57 M Decreased by -18.96% | -2.07 M Decreased by -12.84 K% | Decreased by -17.90% Decreased by -15.87 K% |
| Jul 31, 23 | 12.56 M Decreased by -8.61% | -2.57 M Decreased by -704.39% | Decreased by -20.43% Decreased by -780.21% |
| Apr 30, 23 | 13.07 M Increased by +1.51% | -2.56 M Decreased by -644.48% | Decreased by -19.59% Decreased by -633.43% |
| Jan 31, 23 | 12.77 M Decreased by -3.18% | -2.44 M Decreased by -409.91% | Decreased by -19.09% Decreased by -420.10% |